For investors
The rules of biological compatibility, learned once.
Genome engineering still runs on trial and error. Large Pangenome Models predict which genetic combinations work before anyone touches a bench — and the rules they learn compound with every project.
We are not improving the existing process. We are removing the part of it that fails.
Engineering a living system today means guessing which genes will tolerate each other, then spending years and millions of pounds finding out. Roughly seven in ten complex modifications fail.
Four billion years of evolution has already run that experiment, across millions of genomes. Our Large Pangenome Models read that record and turn it into predictions: which combinations hold, which collapse, and why. Backed by a BBSRC Pioneers grant and a PNAS paper showing pangenome evolution is predictable.
The market
Genome engineering today
- 70% of complex genetic modifications fail
- 3–5 yrs to develop a new biological product
- $100M+ to bring an engineered organism to market
Trial and error, one reference genome at a time.
With Large Pangenome Models
- Predict which gene combinations hold together, before the bench
- Millions of genomes read as one model, not one reference
- Compatibility rules learned from four billion years of natural experiments
The failures get cheap, because they happen in silico.
Why the position defends itself
First mover at pangenome scale
Others model single genomes or single proteins. We model the entire genetic repertoire of a species.
A dataset that is ours
Proprietary pangenomic data spanning multiple kingdoms of life, assembled over two decades of research.
Network effects
Every project sharpens the compatibility rules, which makes the next project faster and cheaper.
Defensible IP
A portfolio covering the algorithms and the processes, not just the outputs.
How it makes money
two revenue lines
Primary
Proprietary products
High-value engineered organisms developed in-house, with full ownership of the IP. Monetised by licensing, partnership or direct commercialisation.
Secondary
Platform & services
Annual platform subscriptions from £50k to £500k, and bespoke design projects from £10k to £100k, at 40–70% gross margin.
Where a Series A goes
Technology
Extend the models to eukaryotic systems and automate the design–test–learn cycle.
Infrastructure
BSL-2/3 laboratory capacity, high-throughput synthesis, and compute.
Team
Senior AI and synthetic biology researchers, plus commercial leadership.
Operations
Market development, regulatory compliance, IP protection.
Next 12–18 months
Complete prokaryotic genome model validation
Secure 3–5 strategic commercial partnerships
Reach first product proof-of-concept
Grow the research team toward 25 people
Who you would be backing
“The history of life on Earth contains the blueprint for solving our most pressing global challenges.”
Professor James McInerney — past President of the Society for Molecular Biology and Evolution, Fellow of the American and European Academies of Microbiology, and 25 years in evolutionary genomics.
Series A
We are raising to take Large Pangenome Models to commercial launch.
All information provided is confidential and proprietary to Pangenome AI Limited.